Mechanisms of action of EGFR tyrosine kinase receptor incorporated in extracellular vesicles

Mechanisms of action of EGFR tyrosine kinase receptor incorporated in extracellular vesicles

EGFR and some of the cognate ligands extensively traffic in extracellular vesicles (EVs) from different biogenesis pathways. EGFR belongs to a family of four homologous tyrosine kinase receptors (TKRs). This family are one of the major drivers of cancer and is involved in several of the most frequen...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Zanetti-Domingues, LC, Martin-Fernandez, ML, Huber, V
Formáid:	Journal article
Teanga:	English
Foilsithe / Cruthaithe:	MDPI 2020

Míreanna comhchosúla

Mechanisms of Action of EGFR Tyrosine Kinase Receptor Incorporated in Extracellular Vesicles
de réir: Laura C. Zanetti-Domingues, et al.
Foilsithe / Cruthaithe: (2020-11-01)

Cooperation and interplay between EGFR signalling and extracellular vesicle biogenesis in cancer
de réir: Zanetti-Domingues, LC, et al.
Foilsithe / Cruthaithe: (2020)

Cooperation and Interplay between EGFR Signalling and Extracellular Vesicle Biogenesis in Cancer
de réir: Laura C. Zanetti-Domingues, et al.
Foilsithe / Cruthaithe: (2020-12-01)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
de réir: Xu H, et al.
Foilsithe / Cruthaithe: (2019-07-01)

Extracellular Vesicles As Mediators of Resistance to EGFR-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Preclinical Models
de réir: M. Pérez-Capó, et al.
Foilsithe / Cruthaithe: (2023-11-01)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
de réir: Lihua Huang, et al.
Foilsithe / Cruthaithe: (2015-09-01)

Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
de réir: Lu Yang, et al.
Foilsithe / Cruthaithe: (2022-06-01)

Radiation-Induced Tumor-Derived Extracellular Vesicles Combined with Tyrosine Kinase Inhibitors: An Effective and Safe Therapeutic Approach for Lung Adenocarcinoma with EGFR19Del
de réir: Yao Li, et al.
Foilsithe / Cruthaithe: (2024-12-01)

HIV Activates the Tyrosine Kinase Hck to Secrete ADAM Protease-Containing Extracellular Vesicles
de réir: J.-H. Lee, et al.
Foilsithe / Cruthaithe: (2018-02-01)

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and IGF-1R
de réir: Cornelius Hempel, et al.
Foilsithe / Cruthaithe: (2017-01-01)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
de réir: Igor Makhlin, et al.
Foilsithe / Cruthaithe: (2019-11-01)

An extracellular receptor tyrosine kinase motif orchestrating intracellular STAT activation
de réir: Katri Vaparanta, et al.
Foilsithe / Cruthaithe: (2022-11-01)

Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors
de réir: Tasia Amelia, et al.
Foilsithe / Cruthaithe: (2022-01-01)

Extracellular vesicle-associated tyrosine kinase-like orphan receptors ROR1 and ROR2 promote breast cancer progression
de réir: Barnabas Irmer, et al.
Foilsithe / Cruthaithe: (2023-07-01)

Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers
de réir: Aude I. Ségaliny, et al.
Foilsithe / Cruthaithe: (2015-03-01)

Editorial: Discovery of EGFR tyrosine kinase inhibitors for cancer treatment
de réir: Panupong Mahalapbutr, et al.
Foilsithe / Cruthaithe: (2024-02-01)

Extracellular Vesicles Act as Nano-Transporters of Tyrosine Kinase Inhibitors to Revert Iodine Avidity in Thyroid Cancer
de réir: Ramya Lakshmi Rajendran, et al.
Foilsithe / Cruthaithe: (2021-02-01)

Moving the Needle Cautiously in Targeting One of the Most Often Acquired Receptor Tyrosine Fusion (RET Fusion) Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors
de réir: Shannon S. Zhang, MD, et al.
Foilsithe / Cruthaithe: (2022-08-01)

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with <i>EGFR</i> Mutations
de réir: Kenichi Suda, et al.
Foilsithe / Cruthaithe: (2021-06-01)

Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure
de réir: Xingyuan Li, et al.
Foilsithe / Cruthaithe: (2023-10-01)

Mechanisms of receptor tyrosine kinase activation in cancer
de réir: Zhenfang Du, et al.
Foilsithe / Cruthaithe: (2018-02-01)

Crystal structure of the Sema-PSI extracellular domain of human RON receptor tyrosine kinase.
de réir: Kinlin L Chao, et al.
Foilsithe / Cruthaithe: (2012-01-01)

Action Mechanisms of Small Extracellular Vesicles in Inflammaging
de réir: Rocío Mato-Basalo, et al.
Foilsithe / Cruthaithe: (2022-04-01)

Osimertinib – effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors
de réir: Marcin Skrzypski, et al.
Foilsithe / Cruthaithe: (2017-09-01)

Primary Resistance to EGFR Tyrosine Kinase Inhibitors (TKIs): Contexts and Comparisons in EGFR-Mutated Lung Cancer
de réir: Keigo Kobayashi
Foilsithe / Cruthaithe: (2023-12-01)

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.
de réir: Daniel B Costa, et al.
Foilsithe / Cruthaithe: (2007-10-01)

EGFR tyrosine kinase activity and Rab GTPases coordinate EGFR trafficking to regulate macrophage activation in sepsis
de réir: Xuedi Zhang, et al.
Foilsithe / Cruthaithe: (2022-11-01)

Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
de réir: Zhe Zhang, et al.
Foilsithe / Cruthaithe: (2019-11-01)

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance
de réir: Tim Fischer, et al.
Foilsithe / Cruthaithe: (2018-01-01)

A preliminary results of integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small-cell-lung cancer harboring EGFR mutation
de réir: K. K. Laktionov, et al.
Foilsithe / Cruthaithe: (2019-06-01)

miR-494 in Extracellular Vesicles as a Potent Biomarker of Chronic Myeloid Leukemia Treatment with Tyrosine Kinase Inhibitors
de réir: Tatsuki Shibuta, et al.
Foilsithe / Cruthaithe: (2022-06-01)

Proteolytic Cleavage of Receptor Tyrosine Kinases
de réir: Hao Huang
Foilsithe / Cruthaithe: (2021-04-01)

Receptor Tyrosine Kinases — Expanding Horizons
de réir: Sassan Hafizi
Foilsithe / Cruthaithe: (2014-06-01)

Extracellular phosphorylation of a receptor tyrosine kinase controls synaptic localization of NMDA receptors and regulates pathological pain.
de réir: Kenji Hanamura, et al.
Foilsithe / Cruthaithe: (2017-07-01)

Mechanisms of Activation of Receptor Tyrosine Kinases: Monomers or Dimers
de réir: Ichiro N. Maruyama
Foilsithe / Cruthaithe: (2014-04-01)

In Vitro Activation and Inhibition of Recombinant EGFR Tyrosine Kinase Expressed in Escherichia coli
de réir: Jihene Elloumi-Mseddi, et al.
Foilsithe / Cruthaithe: (2013-01-01)

Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors
de réir: Nathaniel J. Myall, MD, et al.
Foilsithe / Cruthaithe: (2025-02-01)

ALGORITHMS FOR MANAGEMENT OF PATIENTS WITH ADVERSE EVENTS ON THERAPY WITH TYROSINE KINASE INHIBITORS EGFR
de réir: D. D. SAKAEVA
Foilsithe / Cruthaithe: (2017-06-01)

Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
de réir: Soomin Kim, et al.
Foilsithe / Cruthaithe: (2025-02-01)

The Prediction Of Epidermal Growth Factor Receptor Mutation And Prognosis Of EGFR Tyrosine Kinase Inhibitor By Serum Ferritin In Advanced NSCLC
de réir: Wu Z, et al.
Foilsithe / Cruthaithe: (2019-10-01)